Get the Stockscreener App
6.22
5.33%
-0.35
After Hours:
6.49
0.27
+4.34%
Cingulate Inc stock is traded at $6.22, with a volume of 307.73K.
It is down -5.33% in the last 24 hours and up +27.72% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
See More
Previous Close:
$6.57
Open:
$6.46
24h Volume:
307.73K
Relative Volume:
1.34
Market Cap:
$46.32M
Revenue:
-
Net Income/Loss:
$-22.06M
P/E Ratio:
-1.1763
EPS:
-5.2876
Net Cash Flow:
$-17.93M
1W Performance:
-4.16%
1M Performance:
+27.72%
6M Performance:
+52.08%
1Y Performance:
+37.61%
1-Day Range:
$6.05
$6.535
1-Week Range:
$6.05
$7.92
52-Week Range:
$3.20
$7.92
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
6.22 | 48.92M | 0 | -22.06M | -17.93M | -5.2876 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Peter Werth Purchases 19,455 Shares of Cingulate (NASDAQ:CING) Stock - MarketBeat
Shane Schaffer Buys 6,809 Shares of Cingulate (NASDAQ:CING) Stock - MarketBeat
Cingulate (NASDAQ:CING) CFO Jennifer Callahan Purchases 4,864 Shares - MarketBeat
Aug Technicals: Will DigitalOcean Holdings Inc outperform small cap indexes2025 EndofYear Setup & High Conviction Buy Zone Picks - baoquankhu1.vn
Growth Value: Is Cingulate Inc likely to announce a buybackWeekly Market Outlook & AI Powered Market Entry Ideas - baoquankhu1.vn
Weekly Recap: Is CDROW stock a good dividend stockWeekly Trading Summary & Safe Capital Growth Plans - baoquankhu1.vn
Cingulate Advances Capital Raise with Private Placement Financing - TipRanks
Macro Review: What are analysts price targets for Cingulate Inc Equity Warrant2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
ADHD Drug Maker Cingulate Draws Investor Attention; Stock Up Over 60% In Seven Months - RTTNews
Ideas Watch: Is Cingulate Inc in a long term uptrendQuarterly Investment Review & Weekly Momentum Picks - baoquankhu1.vn
Sentiment Watch: Should I average down on Cineverse Corp stockTrade Exit Report & Weekly Hot Stock Watchlists - baoquankhu1.vn
Cingulate Announces Private Placement and New Preferred Stock - TipRanks
Cingulate Signs Multiple Material Agreements - TradingView
Cingulate Inc. announced that it expects to receive $12.011001 million in funding - marketscreener.com
What’s Cingulate Inc.’s historical returnTrading Volume Surges & The Smart Money Is Buying These Picks - bollywoodhelpline.com
Aug Patterns: What is the target price for Cingulate Inc Equity Warrant stockJuly 2025 Technicals & Community Verified Watchlist Alerts - baoquankhu1.vn
Is Cingulate Inc. stock attractive after correctionJuly 2025 Action & Accurate Buy Signal Alerts - bollywoodhelpline.com
Market Pulse: What is the target price for Cingulate Inc Equity Warrant stockExit Point & Short-Term Trading Alerts - baoquankhu1.vn
Cingulate (NASDAQ:CING) Trading 3.1% Higher – Should You Buy? - Defense World
Cingulate Expands At-The-Market Equity Offering Capacity - The Globe and Mail
Cingulate increases at-the-market offering limit to $31.9 million By Investing.com - Investing.com Canada
Cingulate increases at-the-market offering limit to $31.9 million - Investing.com
Cingulate Inc. Increases Offering Price Under Sales Agreement - TradingView
Quarterly Recap: Is Cingulate Inc likely to announce a buybackJuly 2025 Earnings & Precise Swing Trade Alerts - baoquankhu1.vn
Analysis Recap: Why Cingulate Inc stock appeals to analystsForecast Cut & Real-Time Sentiment Analysis - Bộ Nội Vụ
Market Outlook: Will Cingulate Inc Equity Warrant stock remain a Wall Street favoriteJuly 2025 Reactions & High Win Rate Trade Alerts - Bộ Nội Vụ
Cingulate Inc Files For Mixed Shelf Offering Of Up To $200 Million- SEC Filing - TradingView — Track All Markets
Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug - MSN
Cingulate price target lowered to $16 from $17 at Roth Capital - MSN
Will Cingulate Inc. stock maintain dividend yieldColor and Style Update & trail grip notes for mixed terrain - ulpravda.ru
Why Cingulate Inc. stock remains a top recommendation2025 Breakouts & Breakdowns & Stepwise Swing Trade Plans - Улправда
What analyst consensus says on Cingulate Inc. stockTake Profit & Safe Entry Zone Tips - Улправда
Market Moves: Will Cingulate Inc. stock gain from lower inflationBond Market & Daily Entry Point Trade Alerts - ulpravda.ru
Profit Recap: Is Cingulate Inc. Equity Warrant stock affected by interest rate hikesJuly 2025 Opening Moves & Fast Momentum Stock Entry Tips - Улправда
Is Cingulate Inc. stock oversold or undervaluedQuarterly Trade Review & Low Drawdown Investment Ideas - Улправда
How rising interest rates impact Cingulate Inc. Equity Warrant stockJuly 2025 Summary & Verified Technical Trade Signals - Улправда
Is Cingulate Inc. Equity Warrant stock affected by interest rate hikesWeekly Gains Report & Reliable Price Breakout Signals - Улправда
Is Cingulate Inc. Equity Warrant stock trading at a premium valuation2025 Big Picture & Community Supported Trade Ideas - Улправда
Will Cingulate Inc. Equity Warrant stock gain from lower inflationMarket Risk Summary & High Accuracy Investment Signals - Улправда
How geopolitical tensions affect Cingulate Inc. stockQuarterly Market Review & Long-Term Capital Growth Strategies - Улправда
Will Cingulate Inc. stock continue dividend increasesStock Rotation Strategies & Free High Yield Growth Strategies - Улправда
Crypto: Cingulate, Inc.: The Secret Behind a Stunning 79.64% Surge – Hidden Patterns Revealed - InteractiveCrypto
Cingulate CEO cleared of charges, retains board confidence - MSN
Cingulate continues stock-for-debt exchanges to reduce liabilities - The Globe and Mail
Can Cingulate Inc stock weather global recessionQuarterly Profit Review & Growth Focused Entry Point Reports - Bộ Nội Vụ
Cingulate Inc Equity Warrant Stock Analysis and ForecastMarket Rumors and News & Low Risk Investment Tips - earlytimes.in
Trend Review: Is Cingulate Inc Equity Warrant stock affected by interest rate hikes2025 Big Picture & Low Drawdown Trading Techniques - moha.gov.vn
What technical charts say about Cingulate Inc. Equity Warrant stockMACD Histogram Signals & Minimize Portfolio Damage with Warnings - bollywoodhelpline.com
Cingulate Inc. (NASDAQ:CING) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Why Cingulate Inc stock remains a top recommendation2025 Market Trends & Step-by-Step Trade Execution Guides - moha.gov.vn
Will Cingulate Inc. stock return to pre crisis levelsMarket Insider Reports & Swing Trade Smarter With Data Insights - bollywoodhelpline.com
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):